Paxalisib Clinical Trial Expanded into HR+/HER2- Breast Cancer
“HR+/HER2- breast cancer accounts for approximately 60–70% of all breast cancer diagnoses, and we expect nearly 322,000 new cases in the U.S. alone this year,” said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics. “That scale, combined with the persistent need for better options once patients progress on standard therapy, represents a significant area of unmet medical need where paxalisib may play a role. Our preclinical data showing statistically significant, additive antitumor activity when paxalisib is combined with standard-of-care therapy gives us strong confidence in this approach, and we are moving quickly to bring this combination into the clinic for these patients. With the completion of our recent financing, based on our current plans and projections, we now have the capital in place to fund this program through completion.”
Share:
More News
AstraZeneca announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
“This agreement represents an important step in our strategy to advance our most promising ADC programs efficiently while preserving long-term value,” said Ashutosh Tiwari, PhD, Chief Executive Officer of Styx Biotechnologies. “This collaboration creates a capital-efficient path to first-in-human development by allowing Styx to clinically de-risk selected programs while preserving
“What is most exciting to us is the depth and durability of the responses we are seeing with INBRX-106, particularly in HPV+ disease,” said Mark Lappe, co-founder and Chief Executive Officer of Inhibrx. “These results strengthen our conviction in OX40-mediated T-cell costimulation and give us a strong rationale to expand
“CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche,” said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. “We have generated exciting preclinical data suggesting that TLN-121 enhances